Fluticasone Propionate And Salmeterol Powder
Product Images NDC 0054-0328

This is a description of medication in the form of an inhalation powder for oral use containing Fluticasone Propionate and Salmeterol. Each blister consists of 100 micrograms of Fluticasone Propionate and 72.5 micrograms of Salmeterol Xinafoate, equivalent to 50 micrograms of Salmeterol base along with lactose. The medication is to be used only as per the doctor's prescription and should be discarded after one month of removal from its overwrap. It is distributed by Hikma Pharmaceuticals USA Inc., Berkeley Heights, NJ. The inhaler includes an inhalation device along with one foil strip of 60 blisters, and the patient information leaflet should be carefully read for further details. The medication should be stored at 20°C to 25°C (68°F to 77°F) in a dry place away from sunlight or heat.*

This is a prescription inhalation device that contains Fluticasone Propionate and Salmeterol, each blister containing 250 micrograms of Fluticasone Propionate and 725 micrograms of Salmeterol. It comes with a patient information leaflet that should be read carefully. The inhaler should be stored in a dry place at room temperature and should be discarded a month after removing it from its packaging.*

Fluticasone Propionate and Salmeterol Inhalation Powder 250 mcg/50 mcg is a medication used for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The provided text seems to display a table with values of % change in FEV y (forced expiratory volume in one second) for Fluticasone Propionate and Salmeterol Inhalation Powder 250 mcg/50 mcg, Fluticasone Propionate 250 mcg, and placebo over different time points (Day 1, Week, Endpoint). There are also some numbers beside these time points that could represent sample sizes.*

This appears to be a chart or graph showing the results of a study evaluating the effectiveness of Fluticasone Propionate and Salmeterol Inhalation Powder compared to a control group receiving either Salmeterol or a placebo treatment. The data appears to show improvements in FEV (forced expiratory volume) over the course of the study for those who received the inhalation powder compared to the other groups. However, without more context or information it is difficult to determine the exact nature of the study or the significance of the findings.*

This appears to be a chart or graph displaying the efficacy of various treatments over several weeks for an unknown condition. Without more context, it is not possible to provide a specific description.*

The text shows a chart of the % change in FEV4 for different treatments- Fluticasone Propionate and Salmeterol Inhalation Powder, Salmeterol, Fluticasone Propionate, and Placebo- on the first treatment day. The chart shows results for different time intervals from hour 0 to day 1.*

This appears to be a table presenting data related to two treatments (A and B) for a medical condition that affects breathing, possibly asthma or COPD. The table displays values for FEV (Forced Expiratory Volume) for different time points, including the first day of treatment, the baseline before treatment, week 12, and the last day of treatment. The two treatments tested were A (Fluticasone Propionate and Salmeterol Inhalation Powder 100 mcg/50 mcg twice daily) and B (Fluticasone Propionate 100 mcg twice daily). The number of participants in each treatment group is also provided, along with a placebo group. Overall, this table may give insights into the effectiveness of the two treatments in terms of lung function.*

This appears to be a list of three items with no apparent connection or context. It is not possible to generate a useful description with only this text.*